Treatment of Polycystic Ovarian Syndrome in Adults with BMI 25 kg/m² or Greater

In adult patients with polycystic ovarian syndrome (PCOS) and a body mass index of 25 kg/m² or greater, metabolic considerations are central to the treatment decision. This page summarises the evidence-based approach for this specific population.

Clinical scenario

Adult patients with confirmed PCOS who have a BMI of 25 kg/m² or greater. Elevated BMI in PCOS is associated with adverse metabolic outcomes that directly inform the choice of first-line treatment.

Treatment approach

Evidence supports a single oral agent approach for this population, introduced at a low starting point and escalated gradually to improve tolerability. The complete dosing strategy, escalation schedule, and formulation guidance are detailed in the full protocol.

Clinical targets

The primary therapeutic goals are improvement in glucose and lipid profiles.

Instant Access to Structured Evidence-Based Regimens

References

Metformin alone should be considered in adults with PCOS and a BMI ≥ 25 kg/m² for anthropometric, and metabolic outcomes including insulin resistance, glucose, and lipid profiles.

DOI: 10.1016/j.fertnstert.2023.07.025

View source ↗